IB Inhibrx Biosciences, Inc. Stock: price and insider trades · United States · SEC (Form 4)Track the Inhibrx Biosciences, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.7bn. The latest transaction was disclosed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Lappe Mark. The full history is openly available.
Analyst consensus: bullish or bearish? Analysts rate Inhibrx Biosciences, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$266.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
All Executives31 Thresholds0 Prospectus0 Other0
Declarations 31 total
● Director · Executives · 8 Sept 2026
500 shares @ US$115.14 Common SEC144:0001959173-26-006805
▲ Director · Executives · 8 Sept 2026
2,500 shares @ US$114.6469 0.024% mcap 58.3% of flow Common Stock SEC:0001240801-26-000004:0
Canonical exit: 7 Dec 2026 (T+90) ▲ Chief Executive Officer · Executives · 8 Sept 2026
5,895 shares @ US$99.2948 0.049% mcap 14.6% of flow Common Stock SEC:0001366074-26-000002:0
Canonical exit: 7 Dec 2026 (T+90) ▲ Chief Executive Officer · Executives · 8 Sept 2026
6,605 shares @ US$100.6388 0.055% mcap 16.6% of flow Common Stock SEC:0001366074-26-000002:1
Canonical exit: 7 Dec 2026 (T+90) ▲ Chief Executive Officer · Executives · 8 Sept 2026
1,100 shares @ US$107.1239 0.0098% mcap 2.9% of flow Common Stock SEC:0001366074-26-000002:2
Canonical exit: 7 Dec 2026 (T+90) ▲ Chief Executive Officer · Executives · 8 Sept 2026
500 shares @ US$108.235 0.0045% mcap 1.4% of flow Common Stock SEC:0001366074-26-000002:3
Canonical exit: 7 Dec 2026 (T+90) ▲ Chief Executive Officer · Executives · 8 Sept 2026
1,219 shares @ US$111.8805 0.011% mcap 3.4% of flow Common Stock SEC:0001366074-26-000002:4
Canonical exit: 7 Dec 2026 (T+90) ▲ Chief Executive Officer · Executives · 8 Sept 2026
9,681 shares @ US$112.2819 0.090% mcap 27.2% of flow Common Stock SEC:0001366074-26-000002:5
Canonical exit: 7 Dec 2026 (T+90) ▲ Director · Executives · 8 Sept 2026
5,000 shares @ US$113.516 0.047% mcap 17.5% of flow Common Stock SEC:0001366268-26-000004:0
Canonical exit: 7 Dec 2026 (T+90) 308,643 shares @ US$32.25 100.0% of flow Common Stock SEC:0000905148-25-003555:0
● Director · Executives · 27 Mar 2025
90,000 shares 0Common Stock SEC:0002007919-25-000025:0
● Director · Executives · 16 Dec 2024
500,000 shares 0Common Stock SEC:0002007919-24-000068:0
● Director · Executives · 6 Dec 2024
52,000 shares 0Common Stock SEC:0002007919-24-000066:0
▲ Director · Executives · 19 Nov 2024
34,843 shares @ US$14.2269 20.4% of flow Common Stock SEC:0002007919-24-000064:0
Canonical exit: 17 Feb 2025 (T+90) ▲ Director · Executives · 3 Oct 2024
6,667 shares @ US$15.00 49.4% of flow Common Stock SEC:0002007919-24-000051:0
Canonical exit: 1 Jan 2025 (T+90) ▲ Chief Executive Officer · Executives · 12 Sept 2024
26,963 shares @ US$15.05 31.4% of flow Common Stock SEC:0002007919-24-000049:0
Canonical exit: 11 Dec 2024 (T+90) ▲ Director · Executives · 10 Sept 2024
179 shares @ US$15.00 1.3% of flow Common Stock SEC:0002007919-24-000047:0
Canonical exit: 9 Dec 2024 (T+90) ▲ Chief Executive Officer · Executives · 6 Sept 2024
26,000 shares @ US$15.29 30.7% of flow Common Stock SEC:0002007919-24-000045:0
Canonical exit: 5 Dec 2024 (T+90) ▲ Director · Executives · 29 Aug 2024
7,140 shares @ US$14.00 49.2% of flow Common Stock SEC:0001739614-24-000035:0
Canonical exit: 27 Nov 2024 (T+90) ▲ Chief Executive Officer · Executives · 29 Aug 2024
10,000 shares @ US$14.03 10.9% of flow Common Stock SEC:0001739614-24-000037:0
Canonical exit: 27 Nov 2024 (T+90) ▲ Director · Executives · 28 Aug 2024
10,000 shares @ US$13.98 100.0% of flow Common Stock SEC:0002007919-24-000042:0
Canonical exit: 26 Nov 2024 (T+90) ▲ Director · Executives · 22 Aug 2024
15,188 shares @ US$12.89 100.0% of flow Common Stock SEC:0002007919-24-000040:0
Canonical exit: 20 Nov 2024 (T+90) ▲ Chief Executive Officer · Executives · 20 Aug 2024
27,055 shares @ US$12.97 27.0% of flow Common Stock SEC:0002007919-24-000038:0
Canonical exit: 18 Nov 2024 (T+90) ● Director · Executives · 24 Jun 2024
89,050 shares 0Common Stock SEC:0002007919-24-000024:0
▲ Director · Executives · 5 Jun 2024
49,284 shares @ US$17.23 34.0% of flow Common Stock SEC:0002007919-24-000008:0
Canonical exit: 3 Sept 2024 (T+90) 25 of 31 declarations
Load more (6 remaining) 关于 Inhibrx Biosciences, Inc. Inhibrx Biosciences, Inc. 是一家生物制药公司，专注于开发治疗癌症和其他严重疾病的创新疗法。该公司在纳斯达克上市，股票代码为 INBX。